Andrew Lebovic
Family · Wellington, FLNPI 1710497375
Payments from drug & device makers
Across 195 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$685
- Boehringer Ingelheim$397
- AbbVie$342
- Novo Nordisk$292
- Amgen$200
- Amarin Pharma, Inc.$180
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $685 |
| Boehringer Ingelheim | 18 | $397 |
| AbbVie | 21 | $342 |
| Novo Nordisk | 24 | $292 |
| Amgen | 11 | $200 |
| Amarin Pharma, Inc. | 10 | $180 |
| Pfizer | 7 | $118 |
| AstraZeneca | 6 | $91 |
| GSK | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Abbott | 3 | $68 |
| Johnson & Johnson | 4 | $67 |
| Exact Sciences | 3 | $66 |
| Eisai Inc. | 4 | $65 |
| Novartis | 4 | $59 |
| Bayer | 2 | $51 |
| Merck | 3 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Angiodynamics, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 2 | $26 |
| Mannkind Corporation | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Vistapharm, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,264 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $110,871 |
| JardianceEmpagliflozin | 67 | $74,195 |
| EliquisApixaban | 30 | $22,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $22,335 |
| MounjaroTirzepatide | 14 | $16,963 |
| VascepaIcosapent Ethyl | 15 | $15,646 |
| XareltoRivaroxaban | 19 | $12,433 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $12,320 |
| Repatha SureclickEvolocumab | 12 | $11,051 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $10,956 |
| JanuviaSitagliptin Phosphate | 17 | $10,459 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,081 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $5,138 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 14 | $3,792 |
| Rosuvastatin Calcium | 391 | $3,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $292 | $110,87173 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $397 | $80,27679 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $90 | $33,29130 claims |
| PfizerEliquis | $118 | $22,68430 claims |
| Lilly USA, LLCMounjaro | $685 | $16,96314 claims |
| Johnson & JohnsonXarelto | $67 | $12,43319 claims |
| MerckJanuvia | $39 | $10,45917 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $5,13820 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,158169 claims |
| AbbVieSynthroid | $342 | $95116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Wellington
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.